Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Dr. Pavan K. Cheruvu, M.D., currently serves as Chief Executive Officer and Director of Amanat Acquisition Corp. (Nasdaq: AMAN), a Cayman Islands-incorporated special purpose acquisition company that raised $75 million in its IPO on May 19, 2026, offering 7.5 million common shares at $10 with no warrants or rights. The SPAC, sponsored by Amanat Sponsor Holdings LLC and led by Chairman Sandeep Kulkarni (CEO of Zura Bio and former co-founder and CEO of Tourmaline Bio, which was acquired by Novartis in 2025), targets the healthcare industry with a particular focus on biotechnology and life sciences, seeking to capitalize on the growing backlog of late-stage private biotechnology companies exploring go-public strategies. Leerink Partners served as sole bookrunner on the offering, and the SPAC has a 24-month tenor with 100% of IPO cash held in trust. Cheruvu assumed his role at Amanat on May 18, 2026, and is based in the San Francisco Bay Area, though the company is headquartered in Westfield, New Jersey.
Cheruvu's career spans executive leadership across multiple biotechnology companies, management consulting, clinical medicine, and public policy. He began his professional career as a management consultant at McKinsey & Company, where he focused on R&D strategy and organizational transformation for biopharmaceutical firms across North America, Asia, and Europe. He subsequently joined Roivant Sciences as an early member of the executive team, serving as Chief of Staff and later as Chief People Officer under founder and CEO Vivek Ramaswamy, a fellow Paul & Daisy Soros Fellow. Cheruvu was then named CEO of Axovant Sciences, a clinical-stage biopharmaceutical company, where he prioritized pipeline expansion and operational excellence. He went on to serve as President and CEO of Sio Gene Therapies before becoming President and CEO of Bitterroot Bio, a cardiovascular-focused biotechnology company pioneering the field of cardio-immunology to combat atherosclerosis. He led Bitterroot Bio for nearly four years before transitioning to his current SPAC role. In addition to his Amanat responsibilities, Cheruvu has served as Chairman of the Board of Imbria Pharmaceuticals since September 2025 and sits on the Executive Leadership Team of the American Heart Association's Research Roundtable and the Board of Advisors of Life Sciences Cares Bay Area.
Cheruvu's academic and medical training is exceptionally broad and distinguished. He graduated summa cum laude from Duke University with dual B.S.E. degrees in biomedical engineering and electrical engineering, along with a degree in chemistry. He earned an MSc in Computer Science and an MSc in Neuroscience from the University of Oxford as a Rhodes Scholar (elected in 2002 from the Florida constituency, Balliol College), and subsequently completed his medical degree through the joint Harvard-MIT Health Sciences and Technology (HST) program, supported by a Paul & Daisy Soros Fellowship for New Americans awarded in 2004. He completed his residency in internal medicine at Johns Hopkins Hospital and a clinical fellowship in cardiovascular medicine at the University of California, San Francisco, and is a board-certified physician. Born in Michigan and raised in Tampa, Florida, Cheruvu is the child of immigrants from South India. He lives with his wife, Dr. Deepu Madduri, an oncologist and clinical investigator at Mount Sinai Hospital, and their daughter.
This record is keyed to SEC CIK 0001731741 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 12 institutional-holder rows on these vehicles, under 7 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.